Irbesartan

證據等級: L5

預測適應症: 4 個

Irbesartan: From Hypertension/Diabetic Nephropathy to Malignant Renovascular Hypertension

One-Sentence Summary

Irbesartan is a well-established angiotensin II type 1 (AT₁) receptor blocker (ARB) used for the treatment of hypertension and renoprotection in patients with type 2 diabetes and nephropathy. The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, achieving a prediction score of 99.31%. However, no clinical trials and no direct supporting publications are currently available for this specific indication, and a clinically important safety risk — acute kidney injury in the setting of renal artery stenosis — must be carefully considered.

Quick Overview

Item	Content
Original Indication	Hypertension; renoprotection in type 2 diabetic nephropathy
Predicted New Indication	Malignant Renovascular Hypertension
TxGNN Prediction Score	99.31%
Evidence Level	L5
South Africa Market Status	Not registered
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, formal mechanism of action data is not available in this evidence pack. Based on established pharmacology, Irbesartan is an angiotensin II type 1 (AT₁) receptor antagonist. It competitively and selectively blocks the binding of angiotensin II to AT₁ receptors, thereby inhibiting angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal tubular sodium reabsorption. Its proven renoprotective effects — most notably demonstrated in the landmark IDNT Trial (NEJM 2001) in type 2 diabetic nephropathy — establish its utility in RAAS-driven renal disease.

Malignant renovascular hypertension arises from severe renal artery stenosis, which triggers intense renin release, angiotensin II overproduction, and markedly elevated blood pressure with end-organ damage including hypertensive encephalopathy, retinopathy, and nephropathy. Because the pathophysiology is driven by RAAS over-activation, the mechanistic rationale for an ARB such as Irbesartan is conceptually compelling. This overlap likely accounts for the model’s high confidence score.

However, a critical clinical safety concern tempers this prediction: in the specific setting of significant bilateral renal artery stenosis (or unilateral stenosis in a solitary functioning kidney), the glomerular filtration rate depends heavily on angiotensin II-mediated efferent arteriolar tone to maintain intraglomerular pressure. Blocking this with an ARB can precipitate acute functional kidney injury. This represents a well-recognised class-effect risk that is directly applicable to the predicted indication and must be weighed against any potential benefit.

Clinical Trial Evidence

Currently no related clinical trials registered for Irbesartan in malignant renovascular hypertension.

Literature Evidence

Currently no related literature directly linking Irbesartan to malignant renovascular hypertension is available.

Note on adjacent evidence: A PubMed search for Irbesartan in the related indication pulmonary hypertension owing to lung disease/hypoxia (TxGNN rank 3) returned 20 publications; however, on review these articles address general hypoxia biology (e.g., HIF signalling, neurological effects of hypoxia, tumour hypoxia) and are not directly relevant to Irbesartan’s clinical use in pulmonary hypertension. They are not tabulated as supporting evidence for this report.

South Africa Market Information

Irbesartan is currently not registered with SAHPRA and holds no active product licences in South Africa.

Registration Number	Product Name	Dosage Form	Approved Indication
—	—	—	No registered products found

Regulatory pathway note: Healthcare professionals wishing to use Irbesartan in South Africa may need to apply for access via the SAHPRA Section 21 (unregistered medicines) pathway. Irbesartan is registered and commercially available in multiple other jurisdictions including the European Union, United States (FDA), and United Kingdom (MHRA), and could in principle be sourced through this route pending SAHPRA approval.

Safety Considerations

Detailed SAHPRA-approved safety data (warnings, contraindications, and drug interactions) is not available in this evidence pack.

Please refer to the SAHPRA-approved Professional Information (PI) for full safety information. Report adverse drug reactions to SAHPRA via the MedSafety online reporting system.

Clinically important alert specific to this predicted indication: ARBs — including Irbesartan — are generally contraindicated or must be used with extreme caution in patients with haemodynamically significant bilateral renal artery stenosis, or unilateral stenosis in a solitary kidney. In the specific context of malignant renovascular hypertension, initiating Irbesartan without first confirming the anatomy of the renal vasculature (e.g., via renal Doppler ultrasound or CT angiography) carries a risk of precipitating acute kidney injury. This safety concern is directly relevant to the predicted indication and must be a primary consideration in any clinical decision.

Conclusion and Next Steps

Decision: Hold

Rationale: Although there is a coherent mechanistic basis for Irbesartan in RAAS-driven renovascular disease, there is currently no clinical trial or direct literature evidence to support its use in malignant renovascular hypertension (Evidence Level: L5), and a well-characterised drug class safety risk — acute kidney injury from loss of angiotensin II-dependent efferent tone — poses a potentially serious hazard in precisely this patient population.

To proceed, the following is needed:

Regulatory status: Apply for SAHPRA Section 21 authorisation before any clinical use, given that Irbesartan is currently unregistered in South Africa
Mechanistic data: Obtain complete MOA data from DrugBank or published pharmacology literature to formally support the mechanistic link
Safety clarification: Define the renal artery anatomy threshold (bilateral vs unilateral stenosis, degree of stenosis) below which ARB use may be considered acceptable versus contraindicated in this patient group
Clinical evidence: Commission or identify observational data, case series, or prospective studies examining ARB use in malignant renovascular hypertension
Renal function monitoring plan: Develop a structured monitoring protocol (serum creatinine, eGFR, electrolytes) for any pilot clinical use
Expert consultation: Engage nephrology and hypertension specialists to assess clinical feasibility before moving beyond the research stage

This report is generated for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require rigorous clinical validation before therapeutic application. All information should be interpreted in the context of applicable South African clinical guidelines and SAHPRA regulations.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.